European journal of clinical investigation
-
Eur. J. Clin. Invest. · Jul 2022
Prevalence, characteristics, and impact of Adverse Events in 34 Madrid hospitals. The ESHMAD study.
Adverse Events (AE) are one of the main problems in healthcare. Therefore, many policies have been developed worldwide to mitigate their impact. The Patient Safety Incident Study in Hospitals in the Community of Madrid (ESHMAD) measures the results of them in the region. ⋯ The prevalence of AE remains similar to the previously estimated in studies developed with the same methodology. AE keep leading to longer hospital stays, contributing to patient's death, showing that it is necessary to put focus on patient safety again. A detailed analysis of these events has enabled the detection of specific areas for improvement according to the type of care, centre, and patient.
-
Eur. J. Clin. Invest. · Jul 2022
Multicenter Study Observational StudyCirculating suPAR associates with severity and in-hospital progression of COVID-19.
COVID-19 disease progression is characterized by hyperinflammation and risk stratification may aid in early aggressive treatment and advanced planning. The aim of this study was to assess whether suPAR and other markers measured at hospital admission can predict the severity of COVID-19. ⋯ suPAR levels significantly correlated with WHO-CPS score, with each doubling of suPAR increasing the score by one point. The SALGA model may serve as a quick tool for predicting disease severity and survival at admission.
-
Eur. J. Clin. Invest. · Jul 2022
Clinical TrialPrognostic significance of blood urea nitrogen/creatinine ratio in chronic HFpEF.
The prognostic significance of blood urea nitrogen (BUN)/creatinine ratio specifically in chronic heart failure with preserved ejection fraction (HFpEF) patients remained unclear. We aimed to evaluate the association of BUN/creatinine ratio (baseline level and visit-to-visit variation) with the risk of adverse clinical outcomes among patients with chronic HFpEF. ⋯ Higher BUN/creatinine ratio and greater BUN/creatinine ratio variability are independently associated with adverse outcomes in HFpEF participants in the TOPCAT trial.
-
Eur. J. Clin. Invest. · Jul 2022
Major bleeding in patients with pulmonary embolism presenting with syncope.
Syncope has been shown to be a risk factor of bleeding in patients receiving thrombolytic therapy for acute pulmonary embolism (PE). Whether syncope predicts bleeding in a broader population of patients with PE remains unknown. ⋯ Syncope is a predictor of major bleeding events in patients with PE, even among those receiving anticoagulation monotherapy.
-
Eur. J. Clin. Invest. · Jul 2022
ReviewA comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.
Since the breakthrough of the pandemic, several drugs have been used to treat COVID-19 patients. This review aims to gather information on adverse events (AE) related to most drugs used in this context. ⋯ Some SOCs seem to be more frequent than others among the COVID-19 drugs included, although neither of the studies included reported causality analysis. For that purpose, further clinical studies with robust methodologies, as randomised controlled trials, should be designed and performed.